A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastasesMark Clemons, Dean Fergusson, Phillip Blanchette et al.|Annals of Oncology|2019Cited by 4